Rigel Pharma Scraps Skin Disease Drug
JAK/SYK inhibitor fails phase II trial (October 24)
An investigational dermatologic agent, R333, which was being evaluated as a potential therapeutic for active skin lesions in patients with discoid lupus erythematosus (DLE), did not meet the primary endpoint in a recently completed phase II clinical study. The primary endpoint was the proportion of patients who achieved at least a 50% decrease from baseline in the total combined erythema and scaling score of all treated lesions at week 4.
In light of these findings, the drug’s developer (Rigel Pharmaceuticals) has decided not to pursue this indication further with R333. The decision comes about 2 months after the company stopped the development of an asthma drug.
R333 is a topical Janus kinase/spleen tyrosine kinase (JAK/SYK) inhibitor.